Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation.
Bone Marrow Transplant
; 36(9): 793-6, 2005 Nov.
Article
em En
| MEDLINE
| ID: mdl-16113669
ABSTRACT
Genetic aberrations have emerged as major prognostic factors for patients with multiple myeloma (MM). We evaluated 126 MM patients for t(4;14) or t(11;14), 13q or p53 deletions and correlated the number of genetic aberrations with patient's clinical outcome following undergoing autologous stem cell transplantation. We demonstrate the significance of genetic-based risk classification that clearly segregate patients into low (no genetic abnormalities or only t(11;14)), intermediate (any one of the genetic abnormalities other than t(11;14)) and high-risk groups (any two or more of the genetic abnormalities other than t(11;14)). High-risk patients do not benefit from stem cell transplant and should be offered alternative therapies.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Translocação Genética
/
Proteína Supressora de Tumor p53
/
Deleção Cromossômica
/
Cromossomos Humanos
/
Deleção de Genes
/
Transplante de Células-Tronco
/
Mieloma Múltiplo
Tipo de estudo:
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2005
Tipo de documento:
Article